Actively Recruiting
Biocollection in MyeloDysplastic Syndrome (P-MDS)
Led by University Hospital, Brest · Updated on 2025-02-05
150
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Myelodysplastic syndromes (MDS) are chronic myeloid hemopathies characterized by ineffective hematopoiesis (with peripheral cytopenias) and which contrast with a marrow of normal richness. MDS is considered one of the four most common blood diseases. The incidence is estimated at 4,059 cases / year in 2012 with an average age of 78 years in men and 81 years in women (INCA report, Cancers in France in 2015). The incidence increases with lengthening of the lifespan. The main risk of MDS is transformation to acute leukemia in 30 to 40% of cases. Treatment options depend on clinical, hematologic and chromosomal abnormalities. The prognosis is considered to be at low or high risk of developing acute leukemia. This distinction will therefore have an impact on the therapeutic solution (s). MDS exhibit clinical, morphological and genetic heterogeneity. It is therefore necessary to form subgroups of patients to better understand the physiopathogenesis of this pathology. The constitution of a biocollection will make it possible to search for clinical and biological prognostic markers in order to identify patients progressing to acute myeloid leukemia.
CONDITIONS
Official Title
Biocollection in MyeloDysplastic Syndrome (P-MDS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient diagnosed with or suspected of having myelodysplastic syndrome (WHO definition) at diagnosis or during follow-up
- Managed at the Cancer-Hematology Institute of the Brest CHRU
- Presence of biological material collected within the CRB
- Patient's consent obtained
You will not qualify if you...
- Minor or pregnant woman
- No biological material collected within the CRB
- Refusal to participate or unable to consent
- Patient under judicial protection such as guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu Brest
Brest, France, 29609
Actively Recruiting
Research Team
N
Nathalie Douet-Guilbert, MD, PhD
CONTACT
M
Marie-Bérengère Troadec, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here